Genovate Biotechnology Co Ltd Capital Reinvestment Ratio
Genovate Biotechnology Co Ltd capital reinvestment ratio. Genovate Biotechnology Co Ltd (4130) has a Capital Reinvestment Ratio of 0.48x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$16.93 Million) in capital expenditures (NT$8.19 Million). See Genovate Biotechnology Co Ltd (4130) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Genovate Biotechnology Co Ltd (2015–2025)
Capital reinvestment ratio of Genovate Biotechnology Co Ltd from 2015 to 2025. This chart tracks Genovate Biotechnology Co Ltd's Capital Reinvestment Ratio across 10 annual periods. See how financially flexible is Genovate Biotechnology Co Ltd to measure the company's free cash flow as a share of total liabilities.
Genovate Biotechnology Co Ltd Capital Reinvestment Ratio by Year (2015–2025)
Genovate Biotechnology Co Ltd capital reinvestment ratio by year from 2015 to 2025. For the full cash flow conversion analysis, see Genovate Biotechnology Co Ltd cash conversion from operations.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.40x | NT$43.79 Million | NT$61.42 Million | ▲ +146.4% |
| 2024 | 0.57x | NT$55.11 Million | NT$31.37 Million | ▲ +44.7% |
| 2023 | 0.39x | NT$84.78 Million | NT$33.34 Million | ▼ -97.5% |
| 2022 | 15.90x | NT$1.51 Million | NT$24.01 Million | ▲ +5026.6% |
| 2020 | 0.31x | NT$87.08 Million | NT$27.01 Million | ▼ -46.5% |
| 2019 | 0.58x | NT$44.43 Million | NT$25.76 Million | ▲ +3.4% |
| 2018 | 0.56x | NT$62.88 Million | NT$35.26 Million | ▼ -54.5% |
| 2017 | 1.23x | NT$31.27 Million | NT$38.53 Million | ▲ +112.8% |
| 2016 | 0.58x | NT$70.58 Million | NT$40.87 Million | ▼ -65.0% |
| 2015 | 1.65x | NT$32.53 Million | NT$53.75 Million | — |